Price Point
Total ReturnsTotal Returns (Price + Dividend) 
Aakaar Medical for the last several years.
Risk Adjusted Returns v/s
Returns Beta
News & Corporate ActionsNews
Is Aakaar Medical overvalued or undervalued?
As of 17 November 2025, Aakaar Medical's valuation grade has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. The PE ratio stands at 18.23, while the EV to EBITDA ratio is 12.87, and the ROCE is 15.34%. In comparison to its peers, Aakaar Medical's PE ratio is significantly lower than that of Sun Pharma, which has a PE of 36.69, and Divi's Lab, which is at 69.78. However, it is higher than some peers like Dr. Reddy's Labs, which has a PE of 17.98. The recent performance shows that Aakaar Medical has underperformed the Sensex over the past week and month, with stock returns of -3.24% and -11.37%, respectively, reinforcing the notion of its overvaluation....
Read MoreIs Aakaar Medical overvalued or undervalued?
As of 13 November 2025, Aakaar Medical's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE Ratio of 18.10, an EV to EBIT of 12.95, and a Price to Book Value of 2.32. In comparison to its peers, Aakaar Medical's PE Ratio is considerably lower than that of Sun Pharma Industries at 36.15 and Divi's Lab at 70.4, both categorized as very expensive. Additionally, while Aakaar Medical's EV to EBITDA stands at 12.79, it is still less favorable compared to Torrent Pharma's 32.99. The recent stock performance shows a decline of 8.17% over the past week, contrasting with a 1.45% gain in the Sensex, further supporting the notion of overvaluation....
Read MoreIs Aakaar Medical overvalued or undervalued?
As of 17 September 2025, Aakaar Medical's valuation grade has moved from does not qualify to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 20.94, an EV to EBITDA of 14.77, and a ROE of 26.03%. In comparison to its peers, Aakaar Medical's PE ratio is notably lower than that of Sun Pharma Industries, which has a PE of 33.91, but higher than Cipla's attractive PE of 23.36. The company's PEG ratio stands at 0.00, suggesting a lack of growth expectations compared to its peers. Recent stock performance shows Aakaar Medical outperforming the Sensex over the past week, with a return of 5% compared to the Sensex's 1.43%. Overall, the company's valuation appears stretched relative to its financial performance and peer group....
Read More Announcements
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Key FactorsQuality key factors
Valuation key factors
Technicals key factors
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned ShareholdingShareholding Snapshot : Sep 2025
Shareholding Compare (%holding)
Promoters
None
Held by 0 Schemes
Held by 1 FIIs (0.5%)
Dilip Ramesh Meswani (48.16%)
India Equity Fund 1 (4.96%)
16.47%
FinancialHalf Yearly Results Snapshot (Standalone) - Sep'25
Compare with Peers Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period
Annual Results Snapshot (Standalone) - Mar'25
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period
Company CVAbout Aakaar Medical Technologies Ltd
Company Coordinates
